LYTIR

Company · PTHS

Pelthos Therapeutics Inc.

Nasdaq's symbol directory lists PTHS on NYSE American as “Pelthos Therapeutics Inc. Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 1 occasion ($1.0M); insiders sold on 7 occasions ($109K); 1 filing by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $1.0M in total; Insider sales: $109K in total.Jun: Insider purchases $1.0MJun: Insider sales $8KJul: Insider sales $56KOct: Insider sales $45KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $1.0MInsider sales below: $109K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Todd C. Davis bought on 1 day latest Jun 11, 2026 bought $1.0M
  2. Greenleaf Peter sold on 2 days all under a 10b5-1 plan latest Oct 2, 2026 sold $38K
  3. Pauls Matthew sold on 2 days all under a 10b5-1 plan latest Oct 2, 2026 sold $37K
  4. Friedberg Ezra M sold on 3 days all under a 10b5-1 plan latest Oct 2, 2026 sold $34K
Every trade (8)
  1. SELLGreenleaf Peter sold Oct 2, 2026 797 shares 10b5-1 plan (scheduled) filing $17K
  2. SELLPauls Matthew sold Oct 2, 2026 786 shares 10b5-1 plan (scheduled) filing $17K
  3. SELLFriedberg Ezra M sold Oct 2, 2026 558 shares 10b5-1 plan (scheduled) filing $12K
  4. SELLGreenleaf Peter sold Jul 2, 2026 797 shares 2 legs combined 10b5-1 plan (scheduled) filing $21K
  5. SELLPauls Matthew sold Jul 2, 2026 786 shares 2 legs combined 10b5-1 plan (scheduled) filing $21K
  6. SELLFriedberg Ezra M sold Jul 2, 2026 558 shares 2 legs combined 10b5-1 plan (scheduled) filing $15K
  7. SELLFriedberg Ezra M sold Jun 15, 2026 283 shares 2 legs combined 10b5-1 plan (scheduled) filing $8K
  8. BUYTodd C. Davis bought Jun 11, 2026 35,948 shares 2 legs combined filing $1.0M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Ligand Pharmaceuticals Incorporated filed Nov 3, 2026 Schedule 13D/A may seek influence 5,189,177 shares filing 49.9%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Entry into a material definitive agreement; Creation of a direct financial obligation; Unregistered sales of equity securities; Material modification to rights of security holders; Departure or appointment of directors or officers; Amendments to articles or bylaws; change in fiscal year; Submission of matters to a vote of security holders; Regulation FD disclosure filing Oct 30, 2026
  2. Departure or appointment of directors or officers; Submission of matters to a vote of security holders filing Oct 1, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.